These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 23862654)

  • 1. Clinical, economic and humanistic burdens of skeletal-related events associated with bone metastases.
    Carter JA; Ji X; Botteman MF
    Expert Rev Pharmacoecon Outcomes Res; 2013 Aug; 13(4):483-96. PubMed ID: 23862654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer.
    Delea T; Langer C; McKiernan J; Liss M; Edelsberg J; Brandman J; Sung J; Raut M; Oster G
    Oncology; 2004; 67(5-6):390-6. PubMed ID: 15713995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Canadian health care institution resource utilization resulting from skeletal-related events.
    Habib MJ; Merali T; Mills A; Uon V
    Hosp Pract (1995); 2014 Feb; 42(1):15-22. PubMed ID: 24566592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases.
    Xie J; Namjoshi M; Wu EQ; Parikh K; Diener M; Yu AP; Guo A; Culver KW
    J Manag Care Pharm; 2011 Oct; 17(8):621-43. PubMed ID: 21942303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of denosumab compared with zoledronic acid in patients with breast cancer and bone metastases.
    Xie J; Diener M; Sorg R; Wu EQ; Namjoshi M
    Clin Breast Cancer; 2012 Aug; 12(4):247-58. PubMed ID: 22694824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost of skeletal complications from bone metastases in six European countries.
    Pereira J; Body JJ; Gunther O; Sleeboom H; Hechmati G; Maniadakis N; Terpos E; Acklin YP; Finek J; von Moos R
    J Med Econ; 2016 Jun; 19(6):611-8. PubMed ID: 26849381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The economic burden associated with skeletal-related events in patients with bone metastases secondary to solid tumors in Belgium.
    Body JJ; Chevalier P; Gunther O; Hechmati G; Lamotte M
    J Med Econ; 2013; 16(4):539-46. PubMed ID: 23425250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Healthcare costs associated with skeletal-related events in breast cancer patients with bone metastases.
    Hagiwara M; Delea TE; Chung K
    J Med Econ; 2014 Mar; 17(3):223-30. PubMed ID: 24494707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and economic burden of bone metastasis and skeletal-related events in prostate cancer.
    Yong C; Onukwugha E; Mullins CD
    Curr Opin Oncol; 2014 May; 26(3):274-83. PubMed ID: 24626126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.
    Stopeck A; Rader M; Henry D; Danese M; Halperin M; Cong Z; Qian Y; Dansey R; Chung K
    J Med Econ; 2012; 15(4):712-23. PubMed ID: 22409231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost of skeletal-related events in European patients with solid tumours and bone metastases: data from a prospective multinational observational study.
    Hechmati G; Cure S; Gouépo A; Hoefeler H; Lorusso V; Lüftner D; Duran I; Garzon-Rodriguez C; Ashcroft J; Wei R; Ghelani P; Bahl A
    J Med Econ; 2013; 16(5):691-700. PubMed ID: 23441975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cost of treating skeletal-related events in patients with prostate cancer.
    Lage MJ; Barber BL; Harrison DJ; Jun S
    Am J Manag Care; 2008 May; 14(5):317-22. PubMed ID: 18471035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meta-analysis comparing denosumab and zoledronic acid for treatment of bone metastases in patients with advanced solid tumours.
    Zheng GZ; Chang B; Lin FX; Xie D; Hu QX; Yu GY; Du SX; Li XD
    Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 27430483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrospective database analysis of the effect of zoledronic acid on skeletal-related events and mortality in women with breast cancer and bone metastasis in a managed care plan.
    Henk HJ; Kaura S
    J Med Econ; 2012; 15(1):175-84. PubMed ID: 22017235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The economic burden of skeletal-related events among elderly men with metastatic prostate cancer.
    Jayasekera J; Onukwugha E; Bikov K; Mullins CD; Seal B; Hussain A
    Pharmacoeconomics; 2014 Feb; 32(2):173-91. PubMed ID: 24435407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of denosumab versus zoledronic acid in the management of skeletal metastases secondary to breast cancer.
    Snedecor SJ; Carter JA; Kaura S; Botteman MF
    Clin Ther; 2012 Jun; 34(6):1334-49. PubMed ID: 22578308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of zoledronic acid in the management of skeletal metastases in patients with lung cancer in France, Germany, Portugal, the Netherlands, and the United kingdom.
    Joshi AD; Carter JA; Botteman MF; Kaura S
    Clin Ther; 2011 Mar; 33(3):291-304.e8. PubMed ID: 21600384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health resource utilisation associated with skeletal-related events in patients with bone metastases secondary to solid tumours: regional comparisons in an observational study.
    Duran I; Fink MG; Bahl A; Hoefeler H; Mahmood A; Lüftner D; Ghazal H; Wei R; Chung KC; Hechmati G; Green J; Atchison C
    Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 26865392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequency of skeletal-related events and associated healthcare resource use and costs in US patients with multiple myeloma.
    Nash Smyth E; Conti I; Wooldridge JE; Bowman L; Li L; Nelson DR; Ball DE
    J Med Econ; 2016; 19(5):477-86. PubMed ID: 26671598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival in breast cancer patients with bone metastases and skeletal-related events: a population-based cohort study in Denmark (1999-2007).
    Yong M; Jensen AÖ; Jacobsen JB; Nørgaard M; Fryzek JP; Sørensen HT
    Breast Cancer Res Treat; 2011 Sep; 129(2):495-503. PubMed ID: 21461730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.